SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood
Main finding · Islet autoantibodiesResult — go to the resultHazard ratio 3.5 95% CI 1.6–7.7Authors' conclusion
In young children with high genetic risk of type 1 diabetes, SARS-CoV-2 infection was temporally associated with the development of islet autoantibodies.
Study context
- Population
- Infants aged 4 to 7 months with >10% genetically defined risk of T1D, enrolled in the Primary Oral Insulin Trial, European multicenter; followed up through September 20221,050 enrolled
- Participants
- 885 infants
- Exposure
- SARS-CoV-2 antibody positive vs negative
- SARS-CoV-2 antibodiesn = 170
- Outcome
- Development of multiple (≥2) islet autoantibodies in consecutive samples or single islet antibodies and T1D
Methodological detailsmulticenter, European
- Multicenter
- European
Main finding
Islet autoantibodies
Hazard ratio
3.5
95% CI 1.6–7.7
P = 0.002
By group
SARS-CoV-2 antibodies
7.8 per 100 person-years
CI 5.3–19.0
Without SARS-CoV-2 antibodies
3.5 per 100 person-years
CI 2.2–5.1
SARS-CoV-2 antibodiesvs Without SARS-CoV-2 antibodies
HR 3.5 (95% CI 1.6–7.7); P = 0.002
As reported in the abstract
- Islet autoantibodies developed
- 60 children
- Islet autoantibodies at same visit as SARS-CoV-2 antibodies
- 6
- Islet autoantibodies at visit after SARS-CoV-2 antibodies
- 6
Observational data: associations, not effects.
Further findings
Islet autoantibody risk in SARS-CoV-2 antibody positive children: younger age (<18 months) of SARS-CoV-2 antibody development
- HR, younger age (<18 months) of SARS-CoV-2 antibody development
- 5.3 (95% CI, 1.5-18.3; P = .009)
Age at SARS-CoV-2 antibody development
- Median age, months (range 6-25)
- 18
Original publication
SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood. JAMA. Published 26 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →